

Inventiva to present at six investor conferences in March 2018

Daix (France), March 8, 2018 – Inventiva, a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that its management will present a corporate overview at six upcoming investor conferences in March 2018. The details of the events are as follows:

38th Annual Cowen Healthcare Conference

Date: Monday, March 12, 2018
Time: 4:10pm (Eastern Time)
Location: Boston Marriott Copley Place, Boston

30th Annual ROTH Conference: PPARs: Different Strokes for Different Folks

Date: Tuesday, March 13, 2018
Time: 12:00pm (Eastern Time) / 9:00am (Pacific Time)
Location: The Ritz Carlton Orange County, Newport Beach, CA

30th Annual ROTH Conference: Company presentation

Date: Tuesday, March 13, 2018
Time: 3:30pm (Eastern Time) / 12:30pm (Pacific Time)
Location: The Ritz Carlton Orange County, Newport Beach, CA

2nd Annual H.C. Wainwright NASH Investor Conference

Date: Monday, March 19, 2018
Time: 9:40am (Eastern Time) / 6:00am (Pacific Time)
Location: St. Regis Hotel, New York City

Retail shareholder meeting with the F2iC (French association of retail shareholders) and the Cliff (French association of financial communication professionals)

Date: Monday, March 26, 2018
Time: 2:30pm (Central European Time)
Location: L'Espace Tête d'Or, Lyon-Villeurbanne

KBC Healthcare Conference

Date: Tuesday, March 27, 2018
Location: Brussels

About Inventiva: <http://www.inventivapharma.com>

Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva's research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment with a strong action mechanism permitting the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing in parallel, a second clinical product, odiparcil (formerly IVA336), a treatment for several forms of mucopolysaccharidosis where dermatan and/or chondroitin sulfates GAGs accumulate: MPS I or Hurler/Scheie syndromes, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome, MPS VI or Maroteaux-Lamy syndrome and MPS VII or Sly syndrome. Inventiva is also developing a preclinical stage oncology portfolio.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie. Two strategic R&D partnerships have also been established with AbbVie and Boehringer Ingelheim, making Inventiva eligible for preclinical, clinical, regulatory and commercial milestone payments, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Contacts

Inventiva

Frédéric Cren
Chief Executive Officer
info@inventivapharma.com
+ 33 3 80 44 75 00

Brunswick

Julien Trosdorf / Yannick Tetzlaff
Media relations
inventiva@brunswickgroup.com
+ 33 1 53 96 83 83

LifeSci Advisors

Chris Maggos
Investor relations
chris@lifesciadvisors.com
+ 41 79 367 6254